1AI 0.00% 0.7¢ algorae pharmaceuticals limited

Ann: NTCELL Parkinsons trial patient data 2 years after implant, page-55

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 17,185 Posts.
    lightbulb Created with Sketch. 2426
    That's right, they were very confident based on previous work, but ignored warnings from other studies about the strength and duration of the placebo response. And they were looking for a large response to justify the risks and expense of treatment. They also have a problem in that not all patients are capable of a significant response, but they don't know which ones, nor the optimum dose. A further confounding variable is that all patients are on drug treatment and their performance in the tests may vary from day to day because of things like sleep or emotional state...
    The intention of the study was to provide evidence of sufficient safety and efficacy that they could apply to the local regulators for permission to conduct a larger commercial trial. To do that they would need this trial to show a statistically significant improvement over the controls. The mood seemed optimistic so it would seem likely that the controls in the final cohort may have caused an upset.
 
watchlist Created with Sketch. Add 1AI (ASX) to my watchlist
(20min delay)
Last
0.7¢
Change
0.000(0.00%)
Mkt cap ! $11.81M
Open High Low Value Volume
0.7¢ 0.7¢ 0.7¢ $4.9K 700K

Buyers (Bids)

No. Vol. Price($)
5 1618387 0.6¢
 

Sellers (Offers)

Price($) Vol. No.
0.7¢ 1492067 7
View Market Depth
Last trade - 15.01pm 08/11/2024 (20 minute delay) ?
1AI (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.